Urato Adam C
Tufts University School of Medicine, Maternal-Fetal Medicine Attending Physician, Tufts Medical Center, Boston, MA, USA.
MetroWest Medical Center, Framingham, MA, USA.
Int J Risk Saf Med. 2015;27(2):93-9. doi: 10.3233/JRS-150646.
Rates of antidepressant use during pregnancy are rising worldwide. It is, therefore, essential to determine the effects of these medications in pregnancy and on the developing fetus.
To review the two main explanatory models for understanding the effects of antidepressant use during pregnancy and compare the evidence to support them.
Review, synthesis, and discussion of the available literature.
The preponderance of the basic science, animal data, and human studies supports the view that the Harmful Chemical Model is the best explanatory framework for understanding the effects of the SSRI antidepressants during pregnancy. They do not appear to be helpful medications that produce better outcomes for moms and babies. They are not like using insulin in pregnant diabetics. Their profile fits more with a harmful chemical exposure.
The totality of the scientific evidence convincingly suggests that the SSRI antidepressants are chemicals that do cause fetal harm and that the FDA should strongly consider changing the FDA Category from C to D for the entire class. This move would provide appropriate warning to the public while still allowing for use in selected cases.
全球范围内孕期使用抗抑郁药的比例正在上升。因此,确定这些药物在孕期及对发育中胎儿的影响至关重要。
回顾两种用于理解孕期使用抗抑郁药影响的主要解释模型,并比较支持它们的证据。
对现有文献进行综述、综合和讨论。
基础科学、动物数据和人体研究的大量证据支持这样一种观点,即有害化学物质模型是理解孕期使用选择性5-羟色胺再摄取抑制剂(SSRI)类抗抑郁药影响的最佳解释框架。它们似乎并非能为母亲和婴儿带来更好结局的有益药物。它们与孕期糖尿病患者使用胰岛素不同。其特征更符合有害化学物质暴露。
科学证据的总体情况令人信服地表明,SSRI类抗抑郁药是确实会对胎儿造成伤害的化学物质,美国食品药品监督管理局(FDA)应强烈考虑将整个此类药物的FDA分类从C类改为D类。这一举措将在仍允许在特定情况下使用的同时,向公众提供适当警示。